Therapeutic Efficacy Observation of Rituximab Combined With Low-Dose Glucocorticoids in the Treatment of Idiopathic Membranous Nephropathy
Article Information
Publication Timeline
- Received09 March 2025
- Accepted13 April 2025
Abstract
Objective: To compare the clinical efficacy and safety of rituximab (RTX) combined low-dose glucocorticoid for idiopathic membranous nephropathy (IMN).
Methods: A total of 35 IMN patients were recruited from July,2019 to December, 2023. Control group (n=19): CTX combined glucocorticoid. Experimental group (n=26): rituximab combined low-dose glucocorticoid. The differences of 24-hour urinary protein, serum albumin, blood creatinine, anti-PLA2R antibody titer, disease re-mission rate and adverse reactions were compared between two groups before and at different timepoints post-treatment.
Results: No significant inter-group differences existed in gender, age, body mass index, blood pressure, 24-hour urinary protein, serum albumin, blood creatinine, eGFR or anti-PLA2R antibody count pre-treatment (P>0.05). At Month 6, 24-hour urinary protein declined markedly in 2 groups as compared with pre-treatment (P<0.01); serum level of albumin spiked markedly as compared with pre-treatment (P<0.01). However, no significant inter-group difference existed in reduction of urinary protein and recovery of serum albumin post-treatment (P>0.05). In terms of serum creatinine, total renal function of 2 groups remained stable without statistical significance (P>0.05). Anti-PLA2R-Ab level declined markedly in two groups post-treatment as compared with pre-treatment and the difference was not statistically significant (P>0.05). In terms of disease remission, total effective rate reached 71.43% at Month 6. Meanwhile, recurrence rate was no significant inter-group difference existed in adverse reactions (P>0.05).
Conclusion: With a higher clinical remission rate without a higher incidence of adverse reactions, RTX combined low-dose glucocorticoid is more suitable for treating IMN. However, adverse reactions causing severe hypokalemia deserve greater attention
References
- Hou JH, Zhu HX, Zhou ML, et al. Changes in the spectrum of kidney diseases: an analysis of 40,759 biopsy-proven cases from 2003 to 2014 in China. Kidney Dis. 2018;4(1):10-19. [Google Scholar][Crossref]
- Ronco P, Beck L, Debiec H, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021;7:69. [Google Scholar][Crossref]
- Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983-997. [Google Scholar][Crossref]
- Ronco P, Debiec H. Molecular pathogenesis of membranous nephropathy. Annu Rev Pathol. 2020;15:287-313. [Google Scholar][Crossref]
- Beck LH Jr, Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21. [Google Scholar][Crossref]
- Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494-1506. [Google Scholar][Crossref]
- Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1-S276. [Google Scholar][Crossref]
- Ponticelli C, Escoli R, Moroni G. Does cyclophosphamide still play a role in glomerular diseases? Autoimmun Rev. 2018;17(10):1022-1027. [Google Scholar][Crossref]
- Fernández-Juárez G, Rojas-Rivera J, van de Logt AE, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986-998. [Google Scholar][Crossref]
How to Cite
Ren, H. M., & Quan, Z. L. (2025). Therapeutic Efficacy Observation of Rituximab Combined With Low-Dose Glucocorticoids in the Treatment of Idiopathic Membranous Nephropathy. International Journal of Medical and All Body Health Research, 6(2), 67-70. https://doi.org/10.54660/IJMBHR.2025.6.2.67-70
Ren, Hui-min, and Zheng-li Quan. "Therapeutic Efficacy Observation of Rituximab Combined With Low-Dose Glucocorticoids in the Treatment of Idiopathic Membranous Nephropathy." International Journal of Medical and All Body Health Research, vol. 6, no. 2, 2025, pp. 67-70. https://doi.org/10.54660/IJMBHR.2025.6.2.67-70.
Ren, H. M. and Quan, Z. L. (2025) 'Therapeutic Efficacy Observation of Rituximab Combined With Low-Dose Glucocorticoids in the Treatment of Idiopathic Membranous Nephropathy', International Journal of Medical and All Body Health Research, 6(2), pp. 67-70. doi: 10.54660/IJMBHR.2025.6.2.67-70.
Ren HM, Quan ZL. Therapeutic Efficacy Observation of Rituximab Combined With Low-Dose Glucocorticoids in the Treatment of Idiopathic Membranous Nephropathy. International Journal of Medical and All Body Health Research. 2025;6(2):67-70. doi:10.54660/IJMBHR.2025.6.2.67-70
Similar Articles
- Development of a Label-Free Electrochemical Biosensor for Early Detection of Neurodegenerative Disease Biomarkers Vol 6, Issue 2 (2025)
- Comparative Diagnostic Performance of RIPASA, ALVARADO, and AIR Scoring Systems in Acute Appendicitis: A Retrospective Evaluation Using Traditional Metrics and XGBoost Algorithm Vol 6, Issue 2 (2025)
- Article: The impact of hospital malnutrition on patients in Somalia Vol 6, Issue 2 (2025)
- The Clinical, Subclinical Characteristics and the Factor Associated of Intrauterine Fetal Death at ≥14 Weeks of Pregnancy Vol 6, Issue 2 (2025)
- Demographic, Lifestyle, and Clinical Profile of Diabetic Patients in Mosul’s Primary Health Care: A Cross-Sectional Study Vol 6, Issue 2 (2025)
Find this Article on
Google Scholar Semantic Scholar OpenAlex Scilit Crossref ResearchGate BASEA newly published article may take a few days to appear on these services.